Case presentation 1: Metastatic breast cancer.
In 2015, a 43-year-old Mexican female patient with no relevant medical history discovers a lump in the left breast with bloody discharge from the nipple and was diagnosed as breast cancer. The patient refused treatment. In 2020, the patient suffers a fracture of the hip and was diagnosed with metastasis, simultaneously, she started chemotherapy with abemaciclib 150 mg every 12 h and estrogenic antagonist fulvestrant 250 mg every 4 weeks, metastatic braking was reported. During chemotherapy, the patient had significant side effects such as gastritis, diarrheal episodes, atherosclerosis, hypertension, weight gain, skin dryness, limitation of movement, hair loss, abdominal distention, face rash and leukopenia, a medical reason for intermittent discontinuation of treatment.
In December 2020, concomitant with estrogenic antagonist, the patient started CDS therapy orally, via absorption enema and intravenously. In addition, the patient practices intermittent fasting for 23 hours. Currently the patient is in partial remission, with a thirty-month follow-up (Fig. 1).